Delcath Systems vs Neuropace
Neuropace is the larger business, with $100.0m of revenue in fiscal 2025 against $85.2m for Delcath Systems (1.2 times as much). Delcath Systems grew faster (129.1% against 25.1%). Delcath Systems kept more of each dollar of sales as profit: a net margin of 3.2% against -21.5%. Delcath Systems carries less debt relative to equity (0.0% against 309.4%).
| Latest fiscal year | Delcath SystemsDCTH, 2025 | NeuropaceNPCE, 2025 |
|---|---|---|
| Revenue | $85.2m | $100.0m |
| Revenue growth | 129.1% | 25.1% |
| Net income | $2.7m | −$21.5m |
| Operating margin | 0.8% | -16.3% |
| Net margin | 3.2% | -21.5% |
| Return on equity | 3.0% | -158.7% |
| Free cash flow | $21.0m | −$11.3m |
| Cash | $43.5m | $21.7m |
| Total debt | $0 | $58.9m |
| Debt to equity | 0.0% | 309.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $6.0m | $49.5m |
| Employees | 156 | 209 |
| Market value | $500m | $424m |
| Price vs our value range | — | — |
| Moat score | 25 (Weak) | 37 (Weak) |
| Insider trades, 12 months | 4 buys, 0 sales | 0 buys, 1 sales |